AstraZeneca, a multinational pharmaceutical and biopharmaceutical company, has experienced significant growth in its shares over the past six months. With its stock currently undervalued, the company has made a grand entrance in the pharmaceutical industry by landing a successful deal over a cancer drug and has recorded an all time high jump in the share price. This was facilitated by the drug tariff delay granted by Trump's administration. AstraZeneca is also planning to list its shares directly on the New York Stock Exchange while maintaining its London listing. Moreover, the success of their latest drug, AZD9833, approved by FDA for breast cancer treatment, has led to a surge in their shares. But the optimism was tampered after a rating cut and concerns about the company's pipeline led to a 3% fall in its stock. Simultaneously, AstraZeneca is being positively impacted after a deal concerning drug pricing with the White House and is considered a strong growth and value stock for the long term.
AstraZeneca Stocks News Analytics from Mon, 02 Jun 2025 07:00:00 GMT to Sat, 18 Oct 2025 18:07:00 GMT -
Rating 8
- Innovation 6
- Information 6
- Rumor -7
